Despite their efficacy in inducing deep and durable responses in chronic phase (CP) chronic myeloid leukaemia (CML) patients, BCR-ABL1 tyrosine kinase inhibitors (TKI) do not eradicate leukaemia stem cells (LSC), as proven by the persistence of BCR-ABL1+ CD34+, colony forming, longterm culture-initiating cells in the bone marrow of patients in sustained molecular response 4Á5 (a 4Á5-log reduction of BCR-ABL1 transcript levels, MR4Á5) following TKI therapy (Chomel et al, 2011) .
CML LSC survival is independent of BCR-ABL1 kinase activity (Hamilton et al, 2012) and their quiescence is a putative TKI-resistance mechanism causing disease persistence. Moreover TKI exert anti-proliferative rather than pro-apoptotic effects against CML LSCs and might further contribute to disease persistence (Graham et al, 2002) . Promoting LSC cellcycle entry using granulocyte-colony stimulating factor (G-CSF) has been shown in vitro to restore their sensitivity to TKI and enhance their eradication (Jorgensen et al, 2006) .
Based on this evidence, we performed a randomized phase II study (GIMI, EudraCT 2004-000179-33) , which compared the safety and efficacy of continuous imatinib (cIM) versus pulsed imatinib (pIM) alone or with G-CSF (pIM+G) therapy administered in 4-week cycles for 48 weeks (12 cycles in total) in CP CML patients with at least a complete cytogenetic response (CCyR) on IM ) (see reference for study design, primary and secondary endpoints, patient demographics and disease characteristics). The experimental arms were expected to improve CML LSCs eradication by reducing TKI-induced quiescence (pIM) and/or by actively pushing CML LSCs into cell-cycle (pIM+G). At 2 years follow-up no statistically significant differences for the study endpoints were observed, possibly due to the limited numbers (15 patients per arm). However, 6/30 patients across the two experimental arms exhibited either loss of CCyR or major molecular response (MMR) as compared with only 1/15 in the cIM arm, with all but one patient in the experimental arms regaining MMR on restarting continuous IM or nilotinib therapy ). These results raised some concerns that the experimental schedules might have contributed to the loss of response.
Subsequently, a mathematical model of the safety and efficacy of the IM and G-CSF combination suggested that this approach might be detrimental in the short-to mediumterm for patients with persistent disease treated with IM, by increasing the LSCs burden through enhanced proliferation, thus in turn increasing the risk of acquiring a resistance mutation and of disease progression. However, in the longterm (>2500 d, i.e. 6Á8 years, from start of treatment), such an approach was predicted to prove beneficial as it would deplete the CML LSCs by increasing their susceptibility to TKI (Foo et al, 2009 ).
Here we report the 5-year follow-up data for the GIMI study. 41/45 patients were available for analysis; four patients had died (one only as a result of CML progression). The median follow-up was 5Á67 years. Using an intention to treat analysis, both CCyR and MMR rates were similar among treatment arms with no differences in progression rates. 5/15 patients in the cIM arm compared to 3/15 patients in each experimental arm changed treatment to second generation TKI (Table I) . 
15 (100) 15 (100) 15 (100) Change to second generation TKI † Dasatinib (% of total) 3 (20)
cIM, continous imatinib; pIM, pulsed imatinib; pIM+G, pIM + granulocyte colony-stimulating factor; MMR, major molecular response; CCyR, complete cytogenetic response; CHR, complete haematological response; TKI, tyrosine kinase inhibitor. Note that one patient in the cIM and one patient in the pIM+G arm are currently off TKI therapy but still in MMR or better. *Causes of death were: sudden death (cIM), myocardial infarction (pIM+G), metastatic prostate cancer (pIM+G), progression of chronic myeloid leukaemia (pIM+G). †Causes of interruption of allocated study treatment were: intolerance (n = 3 for cIM and n = 1 for pIM and pIM+G), disease progression (n = 1 for cIM), resistance (n = 1 for pIM arm), suboptimal response (n = 1 for pIM arm and n = 2 for pIM+G arm) and physician's decision (n = 1 for cIM).
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Of note, the reduction in BCR-ABL1 transcript levels between trial entry (baseline) and 5 years was highly statistically significant in both the pIM (1Á10 median log reduction, P = 0Á013) and the pIM+G arms (1Á43 median log reduction, P = 0Á002), while not significant in the cIM arm (1Á06 median log reduction, P = 0Á060) (Fig 1) . However, a comparison of the change from baseline between treatment arms shows that, although this was lower in the cIM arm, it was not significantly different from the change in either the pIM (P = 0Á678) or pIM+G arm (P = 0Á528).
Although the small number of patients demands caution in interpreting these data, these findings are reassuring regarding the safety of the experimental therapeutic approaches. Moreover, the deeper and significant reduction in BCR-ABL1 transcript levels in the experimental arms compared to the cIM arm at 5 years provocatively suggests that in the long-term, as suggested by the mathematical model, these treatment strategies might become beneficial to CP CML patients with persistent disease. However caution is required when making inferences based on the mathematical model of IM and G-CSF treatment, as it predicted the effects of an indefinite duration of this treatment strategy while in our study the combination treatment was only continued for 48 weeks. Nevertheless, considering these findings, we believe that a therapeutic strategy aiming to reverse LSC quiescence in CML combining IM and G-CSF could be safely pursued and only larger studies might be able to provide a definitive answer on its efficacy. 
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